Goldman Sachs
VBIO

Goldman Sachs’s Valion Bio VBIO Stock Holding History

Goldman Sachs’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6
Closed -$1.57K – 6065
2023
Q1 		$1.57K Buy
+6
New +$4.21K ﹤0.01% 5858

Other funds holding VBIO

SSWM
Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
OGC
One68 Global Capital New York $30.9M AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Goldman Sachs's VBIO Position: Q2 2023 in Review

Goldman Sachs sold out of Valion Bio (VBIO) in Q2 2023, closing a stake of 6 shares — an estimated $1.57K sold.

Goldman Sachs first reported a position in VBIO in Q1 2023 and held it in 1 quarter. The position peaked at $1.57K in Q1 2023. 11 funds tracked by Wall St. Rank hold VBIO as of Q2 2023.

  • Goldman Sachs reported no remaining Valion Bio position as of Q2 2023 after selling out during the quarter.
  • Goldman Sachs sold 6 Valion Bio shares in Q2 2023, an estimated $1.57K.
  • Goldman Sachs first reported a position in Valion Bio in Q1 2023 and held it in 1 quarter.
  • Goldman Sachs's Valion Bio position peaked at $1.57K in Q1 2023.
  • 11 funds tracked by Wall St. Rank held Valion Bio as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.